Forum Topic News
  • Conversation: GSK hands rare disease gene therapies over to Orchard

    • April 12, 2018 4:29 PM BST
      • Post(s)

      GSK hands rare disease gene therapies over to Orchard

      Orchard Therapeutics has snapped up GlaxoSmithKline’s portfolio of approved and investigational rare disease gene therapies.
      The deal sees GSK become an investor in Orchard, with a 19.9 percent equity stake along with a seat on the firm’s board. The UK drugs giant also stands to receive royalties and commercial milestone payments related to the acquired portfolio.
      The parties also noted that they intend to share manufacturing, technical and commercial insights and learnings on the development of gene therapy medicines to ensure the success of the assets.
      The programmes acquired by Orchard includes Strimvelis, the first autologous ex vivo gene therapy for children with adenosine deaminase severe combined immunodeficiency (ADA-SCID), approved in Europe in 2016, and two late-stage clinical programmes in ongoing registrational studies for metachromatic leukodystrophy and Wiskott Aldrich syndrome, and one clinical programme for beta thalassaemia.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel